Literature DB >> 33797585

TDP-43 interacts with pathological τ protein in Alzheimer's disease.

Sandra O Tomé1, Luis A Gomes1, Xiaohang Li1, Rik Vandenberghe2,3, Thomas Tousseyn4,5, Dietmar Rudolf Thal6,7.   

Abstract

Entities:  

Year:  2021        PMID： 33797585     DOI： 10.1007/s00401-021-02295-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  12 in total

1.  Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.

Authors:  Shinji Higashi; Eizo Iseki; Ryoko Yamamoto; Michiko Minegishi; Hiroaki Hino; Koshiro Fujisawa; Takashi Togo; Omi Katsuse; Hirotake Uchikado; Yoshiko Furukawa; Kenji Kosaka; Heii Arai
Journal:  Brain Res       Date:  2007-10-25       Impact factor: 3.252

Review 2.  Molecular mechanisms of the co-deposition of multiple pathological proteins in neurodegenerative diseases.

Authors:  Takashi Nonaka; Masami Masuda-Suzukake; Masato Hasegawa
Journal:  Neuropathology       Date:  2017-09-25       Impact factor: 1.906

3.  Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; Amanda M Serie; Ralph B Perkerson; Billie J Matchett; Clifford R Jack; David S Knopman; Ronald C Petersen; Joseph E Parisi; Leonard Petrucelli; Matthew Baker; Rosa Rademakers; Jennifer L Whitwell; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2019-01-02       Impact factor: 17.088

4.  Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology.

Authors:  Ai Kadokura; Tsuneo Yamazaki; Cynthia A Lemere; Masamitsu Takatama; Koichi Okamoto
Journal:  Neuropathology       Date:  2009-04-21       Impact factor: 1.906

5.  Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype.

Authors:  K A Josephs; J L Whitwell; D S Knopman; W T Hu; D A Stroh; M Baker; R Rademakers; B F Boeve; J E Parisi; G E Smith; R J Ivnik; R C Petersen; C R Jack; D W Dickson
Journal:  Neurology       Date:  2008-04-09       Impact factor: 9.910

6.  Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies.

Authors:  Tetsuaki Arai; Ian R A Mackenzie; Masato Hasegawa; Takashi Nonoka; Kazhuhiro Niizato; Kuniaki Tsuchiya; Shuji Iritani; Mitsumoto Onaya; Haruhiko Akiyama
Journal:  Acta Neuropathol       Date:  2009-01-13       Impact factor: 17.088

7.  TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease.

Authors:  Catalina Amador-Ortiz; Wen-Lang Lin; Zeshan Ahmed; David Personett; Peter Davies; Ranjan Duara; Neill R Graff-Radford; Michael L Hutton; Dennis W Dickson
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

8.  Updated TDP-43 in Alzheimer's disease staging scheme.

Authors:  Keith A Josephs; Melissa E Murray; Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Leonard Petrucelli; Amanda M Liesinger; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2016-01-25       Impact factor: 17.088

9.  Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report.

Authors:  Peter T Nelson; Dennis W Dickson; John Q Trojanowski; Clifford R Jack; Patricia A Boyle; Konstantinos Arfanakis; Rosa Rademakers; Irina Alafuzoff; Johannes Attems; Carol Brayne; Ian T S Coyle-Gilchrist; Helena C Chui; David W Fardo; Margaret E Flanagan; Glenda Halliday; Suvi R K Hokkanen; Sally Hunter; Gregory A Jicha; Yuriko Katsumata; Claudia H Kawas; C Dirk Keene; Gabor G Kovacs; Walter A Kukull; Allan I Levey; Nazanin Makkinejad; Thomas J Montine; Shigeo Murayama; Melissa E Murray; Sukriti Nag; Robert A Rissman; William W Seeley; Reisa A Sperling; Charles L White; Lei Yu; Julie A Schneider
Journal:  Brain       Date:  2019-06-01       Impact factor: 15.255

10.  Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes.

Authors:  Manuela Neumann; Petra Frick; Francesca Paron; Jonas Kosten; Emanuele Buratti; Ian R Mackenzie
Journal:  Acta Neuropathol       Date:  2020-08-10       Impact factor: 17.088
View more
  8 in total

1.  Association of Cognition and Dementia With Neuropathologic Changes of Alzheimer Disease and Other Conditions in the Oldest-Old.

Authors:  Thomas J Montine; Maria M Corrada; Claudia Kawas; Syed Bukhari; Lon White; Lu Tian; Brenna Cholerton
Journal:  Neurology       Date:  2022-06-15       Impact factor: 11.800

2.  Loss of aly/ALYREF suppresses toxicity in both tau and TDP-43 models of neurodegeneration.

Authors:  Rebecca L Kow; Aristide H Black; Aleen D Saxton; Nicole F Liachko; Brian C Kraemer
Journal:  Geroscience       Date:  2022-02-04       Impact factor: 7.581

3.  Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease.

Authors:  Maiko T Uemura; John L Robinson; Katheryn A Q Cousins; Thomas F Tropea; Daniel C Kargilis; Jennifer D McBride; EunRan Suh; Sharon X Xie; Yan Xu; Sílvia Porta; Norihito Uemura; Vivianna M Van Deerlin; David A Wolk; David J Irwin; Kurt R Brunden; Virginia M-Y Lee; Edward B Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2021-12-02       Impact factor: 15.887

4.  Developmental deficits and staging of dynamics of age associated Alzheimer's disease neurodegeneration and neuronal loss in subjects with Down syndrome.

Authors:  Jerzy Wegiel; Michael Flory; Izabela Kuchna; Krzysztof Nowicki; Jarek Wegiel; Shuang Yong Ma; Nanbert Zhong; Teresa Wierzba Bobrowicz; Mony de Leon; Florence Lai; Wayne P Silverman; Thomas Wisniewski
Journal:  Acta Neuropathol Commun       Date:  2022-01-04       Impact factor: 7.801

Review 5.  Tau mRNA Metabolism in Neurodegenerative Diseases: A Tangle Journey.

Authors:  Paulo J da Costa; Malika Hamdane; Luc Buée; Franck Martin
Journal:  Biomedicines       Date:  2022-01-23

6.  TDP-43 promotes tau accumulation and selective neurotoxicity in bigenic Caenorhabditis elegans.

Authors:  Caitlin S Latimer; Jade G Stair; Joshua C Hincks; Heather N Currey; Thomas D Bird; C Dirk Keene; Brian C Kraemer; Nicole F Liachko
Journal:  Dis Model Mech       Date:  2022-04-27       Impact factor: 5.732

7.  LATE-NC aggravates GVD-mediated necroptosis in Alzheimer's disease.

Authors:  Marta J Koper; Sandra O Tomé; Klara Gawor; Annelies Belet; Evelien Van Schoor; Jolien Schaeverbeke; Rik Vandenberghe; Mathieu Vandenbulcke; Estifanos Ghebremedhin; Markus Otto; Christine A F von Arnim; Sriram Balusu; Matthew B Blaschko; Bart De Strooper; Dietmar Rudolf Thal
Journal:  Acta Neuropathol Commun       Date:  2022-09-03       Impact factor: 7.578

8.  Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer's disease.

Authors:  Caitlin S Latimer; Nicole F Liachko
Journal:  Geroscience       Date:  2021-06-29       Impact factor: 7.713
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.